(November 9, 2017, 3:15 PM EST) -- NEW YORK — Dismissal of a second amended shareholder class action lawsuit against a drug maker and certain of its current and former executive officers is warranted because the lead plaintiff in the action failed to state any actionable misrepresentations or scienter in making federal securities law claims, defendants argue in a Nov. 3 motion to dismiss filed in New York federal court (In re Insys Therapeutics Inc. Securities Litigation, No. 17-1954, S.D. N.Y.)....